FDA Approves CMV Test for Baby Virus Hunt
Published Date: 5/9/2025
Rule
Summary
The FDA is officially putting a new test for detecting congenital cytomegalovirus (CMV) into a special safety category called Class II. This means the test will have clear rules to make sure it’s safe and works well, helping doctors and patients get access to this important tool faster. This change affects device makers and healthcare providers and aims to speed up innovation without extra costs or delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Manufacturers Face Class II Rules
If you make medical tests for congenital cytomegalovirus (CMV), the FDA has put the CMV nucleic acid detection device into Class II with special controls. That gives clear, codified safety and performance rules and is intended to reduce regulatory burdens for device makers so innovation can move faster.
Faster Patient Access to CMV Tests
If you are a parent or patient needing congenital CMV testing, the FDA's Class II classification for the CMV nucleic acid detection device is intended to enhance patient access to these diagnostic tests. The agency says the change should help speed innovation and improve access without adding extra costs or delays.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Previous / Next Documents
Previous: 2025-08145, Medical Devices; Immunology and Microbiology Devices; Classification of the Microbial Nucleic Acid Storage and Stabilization Device
The FDA is officially putting microbial nucleic acid storage and stabilization devices into a special safety category called Class II. This means these devices will have clear rules to keep them safe and effective, helping patients get better access to cool new medical tech faster. If you make or use these devices, expect smoother approvals and no surprise costs or delays.
Next: 2025-08147, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Breast Milk Macronutrients Test System
The FDA is officially putting breast milk macronutrient test systems into a special safety group called Class II. This means these devices will have clear rules to keep them safe and effective, helping moms and babies get better access to these helpful tools faster. This change cuts red tape without adding extra costs, making it easier for companies to bring these devices to market.